医学
转移性乳腺癌
热烧蚀
肿瘤科
内科学
多学科方法
队列
队列研究
乳腺癌
烧蚀
总体生存率
回顾性队列研究
癌症
转移
放射科
多学科团队
全身疗法
癌症登记处
作者
Nadia Bianco,Carmine Valenza,Monica Milano,Roberta Multinu,Elena Battaiotto,Matteo Cavallone,Giulia Malvezzi,Dario Trapani,Paolo Della Vigna,Guido Bonomo,Gianluca Maria Varano,Daniele Maiettini,Maria Giovanna Pitoni,Claudia Sangalli,Elisabetta Munzone,Giuseppe Curigliano,Marco Colleoni,Franco Orsi
出处
期刊:The Breast
[Elsevier BV]
日期:2025-11-26
卷期号:85: 104667-104667
被引量:1
标识
DOI:10.1016/j.breast.2025.104667
摘要
BACKGROUND: Patients with visceral oligoprogressive and oligopersistent metastatic breast cancer (mBC) may benefit from metastasis-directed thermal ablation (TA) to all sites of metastasis, while maintaining the same systemic treatment, in order to delay the time to treatment failure (TTF). This study aims to assess the outcomes provided by this multimodal strategy. METHODS: We conducted a single-center, cohort study including consecutive patients with visceral oligoprogressive and oligopersistent mBC as per ESTRO/EORTC criteria, who underwent TA to all sites. Oligoprogression was defined as progressive disease in ≤5 metastatic sites with at least one other metastatic site maintaining the disease control; oligopersistence as ≤5 persistent lesions after systemic therapy. The main endpoint was post-TA progression-free survival (pTA-PFS). RESULTS: 43 patients with oligoprogressive (cohort A) and 43 with oligopersistent (cohort B) disease were included; 4 (5 %) reported a TA-related adverse event. Overall, 122 visceral lesions were treated. In cohort A, median PFS before oligoprogression was 14.9 months (95 % CI, 9.7-20.1). After TA, 32 patients continued the same systemic treatment and 11 switched therapy; pTA-PFS was 9.1 months (95 % CI, 4.8-13.4), unchanged after excluding patients who switched systemic therapy. In cohort B, median PFS before oligopersistence was 7.8 months (95 % CI, 7.4-8.3). After TA, 35 patients continued the same systemic treatment, while 8 de-intensified to maintenance therapy; pTA-PFS was 16.7 months (95 % CI, 11.1-22.2). CONCLUSION: Selected patients with visceral oligoprogressive and oligopersistent mBC appear to benefit from TA and systemic treatment continuation or modulation. This strategy can be implemented for selected patients in the framework of a multidisciplinary tumor board's shared decision.
科研通智能强力驱动
Strongly Powered by AbleSci AI